Macrocycles in new drug discovery.
暂无分享,去创建一个
[1] Matthew P Jacobson,et al. Testing the conformational hypothesis of passive membrane permeability using synthetic cyclic peptide diastereomers. , 2006, Journal of the American Chemical Society.
[2] Martin Brassard,et al. Optimization of the potency and pharmacokinetic properties of a macrocyclic ghrelin receptor agonist (Part I): Development of ulimorelin (TZP-101) from hit to clinic. , 2011, Journal of medicinal chemistry.
[3] Anders Poulsen,et al. Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lympho , 2011, Journal of medicinal chemistry.
[4] F. Totzke,et al. Diversity-oriented synthesis of pochonins and biological evaluation against a panel of kinases. , 2006, Chemistry.
[5] A. Mann. Conformational Restriction and/or Steric Hindrance in Medicinal Chemistry , 2008 .
[6] R. Stupp,et al. Cilengitide in newly diagnosed glioblastoma with MGMT promoter methylation: Protocol of a multicenter, randomized, open-label, controlled phase III trial (CENTRIC). , 2010 .
[7] S. Barluenga,et al. Synthesis of a resorcylic acid lactone (RAL) library using fluorous-mixture synthesis and profile of its selectivity against a panel of kinases. , 2009, Chemistry.
[8] H. Hirai,et al. Structure-based drug design of a highly potent CDK1,2,4,6 inhibitor with novel macrocyclic quinoxalin-2-one structure. , 2006, Bioorganic & medicinal chemistry letters.
[9] Ian Collins,et al. New approaches to molecular cancer therapeutics , 2006, Nature chemical biology.
[10] David R. Liu,et al. Translation of DNA into a library of 13,000 synthetic small-molecule macrocycles suitable for in vitro selection. , 2008, Journal of the American Chemical Society.
[11] Alan L Harvey,et al. Natural products in drug discovery. , 2008, Drug discovery today.
[12] P. Atadja,et al. Conformational refinement of hydroxamate-based histone deacetylase inhibitors and exploration of 3-piperidin-3-ylindole analogues of dacinostat (LAQ824). , 2010, Journal of medicinal chemistry.
[13] Matthew P Jacobson,et al. Conformational flexibility, internal hydrogen bonding, and passive membrane permeability: successful in silico prediction of the relative permeabilities of cyclic peptides. , 2006, Journal of the American Chemical Society.
[14] S. Barluenga,et al. Concise synthesis of pochonin A, an HSP90 inhibitor. , 2005, Organic letters.
[15] M. Vandermeeren,et al. Macrocyclic BACE inhibitors: Optimization of a micromolar hit to nanomolar leads. , 2010, Bioorganic & medicinal chemistry letters.
[16] J. H. Clements,et al. Thermodynamic and Structural Effects of Macrocyclization as a Constraining Method in Protein-Ligand Interactions. , 2010, ACS medicinal chemistry letters.
[17] T. Ritchie,et al. The impact of aromatic ring count on compound developability--are too many aromatic rings a liability in drug design? , 2009, Drug discovery today.
[18] F. Lombardo,et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.
[19] Jun-ichi Yoshida,et al. Continuous flow synthesis. , 2013, Drug discovery today. Technologies.
[20] S. Benkovic,et al. Cyclic Peptides, A Chemical Genetics Tool for Biologists , 2005, Cell cycle.
[21] S. Goodin. Ixabepilone: a novel microtubule-stabilizing agent for the treatment of metastatic breast cancer. , 2008, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[22] Horst Kessler,et al. Reinvestigation of the Conformation of Cyclosporin A in Chloroform , 1990 .
[23] Alessia Pica,et al. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] L. To,et al. Results of a Phase 2 Study of Pacritinib (SB1518), a Novel Oral JAK2 Inhibitor, In Patients with Primary, Post-Polycythemia Vera, and Post-Essential Thrombocythemia Myelofibrosis , 2011 .
[25] S. Goodin. Novel cytotoxic agents: epothilones. , 2008, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[26] Glen E Kellogg,et al. Hydrophobicity--shake flasks, protein folding and drug discovery. , 2010, Current topics in medicinal chemistry.
[27] J. Levin,et al. Design and SAR of macrocyclic Hsp90 inhibitors with increased metabolic stability and potent cell-proliferation activity. , 2011, Bioorganic & medicinal chemistry letters.
[28] Chang Park,et al. Structure-based design, synthesis, and biological evaluation of potent and selective macrocyclic checkpoint kinase 1 inhibitors. , 2007, Journal of medicinal chemistry.
[29] A. Bogdan,et al. Comparison of diffusion coefficients for matched pairs of macrocyclic and linear molecules over a drug-like molecular weight range. , 2011, Organic & biomolecular chemistry.
[30] Victoria A Johnson,et al. Macrocyclic inhibitors of hsp90. , 2010, Current topics in medicinal chemistry.
[31] A. Ghose,et al. Design, synthesis, and anaplastic lymphoma kinase (ALK) inhibitory activity for a novel series of 2,4,8,22-tetraazatetracyclo[14.3.1.1³,⁷.1⁹,¹³]docosa-1(20),3(22),4,6,9(21),10,12,16,18-nonaene macrocycles. , 2012, Journal of medicinal chemistry.
[32] H. Briem,et al. Macrocyclic Aminopyrimidines as Multitarget CDK and VEGF‐R Inhibitors with Potent Antiproliferative Activities , 2007, ChemMedChem.
[33] Laura G. Dubois,et al. Discovery of novel 2-aminobenzamide inhibitors of heat shock protein 90 as potent, selective and orally active antitumor agents. , 2009, Journal of medicinal chemistry.
[34] E. Raymond,et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] Paul Workman,et al. Inhibitors of the HSP90 molecular chaperone: attacking the master regulator in cancer. , 2006, Current topics in medicinal chemistry.
[36] Synthesis of cyclic peptides constrained with biarylamine linkers using Buchwald-Hartwig C-N coupling. , 2006, The Journal of organic chemistry.
[37] Junya Qu,et al. 2-Amino-3,4-dihydroquinazolines as inhibitors of BACE-1 (beta-site APP cleaving enzyme): Use of structure based design to convert a micromolar hit into a nanomolar lead. , 2007, Journal of medicinal chemistry.
[38] P. Clemons,et al. Route to three-dimensional fragments using diversity-oriented synthesis , 2011, Proceedings of the National Academy of Sciences.
[39] Stephen P. Hale,et al. The exploration of macrocycles for drug discovery — an underexploited structural class , 2008, Nature Reviews Drug Discovery.
[40] Dudley H. Williams,et al. Changes in motion vs. bonding in positively vs. negatively cooperative interactions. , 2002, Chemical communications.
[41] Christopher J. White,et al. Contemporary strategies for peptide macrocyclization. , 2011, Nature chemistry.
[42] A. Hopkins,et al. Ligand efficiency: a useful metric for lead selection. , 2004, Drug discovery today.
[43] J. Levin,et al. Macrocyclic lactams as potent Hsp90 inhibitors with excellent tumor exposure and extended biomarker activity. , 2011, Bioorganic & medicinal chemistry letters.
[44] Paul Workman,et al. Inhibition of Hsp90 with synthetic macrolactones: synthesis and structural and biological evaluation of ring and conformational analogs of radicicol. , 2006, Chemistry & biology.
[45] C. Gilon,et al. Structure-activity relationship and metabolic stability studies of backbone cyclization and N-methylation of melanocortin peptides. , 2008, Biopolymers.
[46] S. Barluenga,et al. Divergent syntheses of resorcylic acid lactones: L-783277, LL-Z1640-2, and hypothemycin. , 2009, Chemistry.
[47] M. Hann. Molecular obesity, potency and other addictions in drug discovery , 2011 .
[48] Min Ju Kim,et al. Novel macrocyclic C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents. , 2011, Bioorganic & medicinal chemistry.
[49] Andrew G. Leach,et al. Comparison of the ATP binding sites of protein kinases using conformationally diverse bisindolylmaleimides. , 2005, Journal of the American Chemical Society.
[50] J. Hunt. Discovery of Ixabepilone , 2009, Molecular Cancer Therapeutics.
[51] G. Kroemer,et al. Current development of mTOR inhibitors as anticancer agents , 2006, Nature Reviews Drug Discovery.
[52] S. Brown,et al. Hydration changes implicated in the remarkable temperature-dependent membrane permeation of cyclosporin A. , 2000, Biochemistry.
[53] H. Hirai,et al. Potent anti-tumor activity of a macrocycle-quinoxalinone class pan-Cdk inhibitor in vitro and in vivo , 2011, Investigational New Drugs.
[54] C. Humblet,et al. Escape from flatland: increasing saturation as an approach to improving clinical success. , 2009, Journal of medicinal chemistry.
[55] N. Terrett,et al. Methods for the synthesis of macrocycle libraries for drug discovery. , 2010, Drug discovery today. Technologies.
[56] Ludger A. Wessjohann,et al. What can a chemist learn from nature’s macrocycles? – A brief, conceptual view , 2005, Molecular Diversity.
[57] L. Pearl,et al. Targeting the Hsp90 molecular chaperone with novel macrolactams. Synthesis, structural, binding, and cellular studies. , 2011, ACS chemical biology.
[58] H. Ye,et al. Novel bis(indolyl)maleimide pyridinophanes that are potent, selective inhibitors of glycogen synthase kinase-3. , 2007, Bioorganic & medicinal chemistry letters.
[59] Ben Cornett,et al. The Binding Mode of Epothilone A on α,ß-Tubulin by Electron Crystallography , 2004, Science.
[60] Vincenzo Summa,et al. Advances in the development of macrocyclic inhibitors of hepatitis C virus NS3-4A protease. , 2010, Current topics in medicinal chemistry.
[61] Jerry March,et al. March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure , 2001 .
[62] R. Pazdur,et al. FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma. , 2010, The oncologist.
[63] C. Perretta,et al. Structure-based design and synthesis of novel macrocyclic pyrazolo[1,5-a] [1,3,5]triazine compounds as potent inhibitors of protein kinase CK2 and their anticancer activities. , 2008, Bioorganic & medicinal chemistry letters.
[64] S. Lakhani,et al. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[65] Wolfgang Brandt,et al. Chemoinformatic analysis of biologically active macrocycles. , 2010, Current topics in medicinal chemistry.
[66] Sandra C. Mwakwari,et al. Macrocyclic histone deacetylase inhibitors. , 2010, Current topics in medicinal chemistry.
[67] Andrew V. Anzalone,et al. Novel 2,3,4,5-tetrahydro-benzo[d]azepine derivatives of 2,4-diaminopyrimidine, selective and orally bioavailable ALK inhibitors with antitumor efficacy in ALCL mouse models. , 2011, Bioorganic & medicinal chemistry letters.
[68] Sivaraman Dandapani,et al. Grand challenge commentary: Accessing new chemical space for 'undruggable' targets. , 2010, Nature chemical biology.
[69] Minoru Ishikawa,et al. Improvement in aqueous solubility in small molecule drug discovery programs by disruption of molecular planarity and symmetry. , 2011, Journal of medicinal chemistry.
[70] Li Xing,et al. Influence of molecular flexibility and polar surface area metrics on oral bioavailability in the rat. , 2004, Journal of medicinal chemistry.
[71] D. Heinz,et al. Much anticipated--the bioactive conformation of epothilone and its binding to tubulin. , 2005, Angewandte Chemie.
[72] Stuart L. Schreiber,et al. Structure of the FKBP12-Rapamycin Complex Interacting with Binding Domain of Human FRAP , 1996, Science.
[73] J. Levin,et al. Discovery of a macrocyclic o-aminobenzamide Hsp90 inhibitor with heterocyclic tether that shows extended biomarker activity and in vivo efficacy in a mouse xenograft model. , 2011, Bioorganic & medicinal chemistry letters.
[74] A. Bogdan,et al. Synthesis of 5-iodo-1,2,3-triazole-containing macrocycles using copper flow reactor technology. , 2011, Organic letters.
[75] M. Holloway,et al. Thermodynamics of ligand binding and efficiency. , 2011, ACS medicinal chemistry letters.
[76] Ian A. Watson,et al. Characteristic physical properties and structural fragments of marketed oral drugs. , 2004, Journal of medicinal chemistry.
[77] J. Wood,et al. Discovery of kinase spectrum selective macrocycle (16E)-14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (SB1317/TG02), a potent inhibitor of cyclin dependent kinases (CDKs), Janus kinase 2 (JAK2), and fms-like tyrosine kinase- , 2012, Journal of medicinal chemistry.
[78] A. Oyelere,et al. Editorial [Hot topic: Macrocycles in Medicinal Chemistry and Drug Discovery (Guest Editors: Adegboyega K. Oyelere)] , 2010 .
[79] Horst Kessler,et al. Cilengitide: The First Anti-Angiogenic Small Molecule Drug Candidate. Design, Synthesis and Clinical Evaluation , 2010, Anti-cancer agents in medicinal chemistry.
[80] R. Schrock,et al. Synthesis of macrocyclic natural products by catalyst-controlled stereoselective ring-closing metathesis , 2011, Nature.
[81] J. Levin,et al. Discovery of a stable macrocyclic o-aminobenzamide Hsp90 inhibitor which significantly decreases tumor volume in a mouse xenograft model. , 2011, Bioorganic & medicinal chemistry letters.
[82] Jerry March,et al. Advanced Organic Chemistry: Reactions, Mechanisms, and Structure , 1977 .
[83] Stephen R. Johnson,et al. Molecular properties that influence the oral bioavailability of drug candidates. , 2002, Journal of medicinal chemistry.
[84] É. Marsault,et al. Macrocycles are great cycles: applications, opportunities, and challenges of synthetic macrocycles in drug discovery. , 2011, Journal of medicinal chemistry.
[85] R. Grubbs,et al. Formation of macrocycles via ring-closing olefin metathesis. , 2001, The Journal of organic chemistry.
[86] M. Katharine Holloway,et al. Macrocyclic Inhibitors of β-Secretase: Functional Activity in an Animal Model. , 2006 .
[87] Z. Tao,et al. Synthesis of Macrocyclic Urea Kinase Inhibitors , 2007 .
[88] S. Barluenga,et al. Chemistry and biology of resorcylic acid lactones. , 2007, Chemical communications.
[89] C. Dalvit,et al. Conformation of cyclosporin A in polar solvents. , 2009, International journal of peptide and protein research.
[90] P. Leeson,et al. 3-(1-piperazinyl)-4,5-dihydro-1H-benzo[g]indazoles: high affinity ligands for the human dopamine D4 receptor with improved selectivity over ion channels. , 1998, Bioorganic & medicinal chemistry.
[91] K. James,et al. CuAAC macrocyclization: high intramolecular selectivity through the use of copper-tris(triazole) ligand complexes. , 2011, Organic letters.
[92] N. Borkakoti,et al. Design and synthesis of potent macrocyclic renin inhibitors. , 2011, Bioorganic & medicinal chemistry letters.
[93] M. Rudd,et al. Discovery of MK-1220: A Macrocyclic Inhibitor of Hepatitis C Virus NS3/4A Protease with Improved Preclinical Plasma Exposure. , 2011, ACS medicinal chemistry letters.
[94] Flavien Susanne,et al. Continuous flow synthesis. A pharma perspective. , 2012, Journal of medicinal chemistry.
[95] F. Totzke,et al. Modular synthesis of radicicol A and related resorcylic acid lactones, potent kinase inhibitors. , 2007, Angewandte Chemie.
[96] A. Poulsen,et al. SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies , 2011, Leukemia.
[97] C. Lipinski. Compound Properties and Drug Quality , 2008 .